FDA places Chinese, Indian generic drugmakers on ‘Red List’ for not paying fees

FDA
FDA adds manufacturers to 'Red List'.

The FDA has placed four Chinese and Indian generic drug facilities on the so-called “Red List” that bans them from shipping products to the U.S. for failing to pay required fees and not meeting identification requirements.

The action by the regulatory agency falls under the Generic Drug User Fee Amendments of 2012.

“Placing these firms on import alerts is the first time the FDA is using the authority provided by Congress to enforce GDUFA’s user fee provisions," Kris Baumgartner, an agency spokesman, told the Regulatory Affairs Professionals Society’s publication Focus.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Named by the FDA to the ban are Jiangsu ZW Pharmaceuticals and Wuxi Kaili Pharmaceutical, both of China and both which received warning letters in 2015; and Fleming Laboratories and Sharon Bio-Medicine, both of India. Fleming got an FDA warning letter in 2014, and Sharon Bio-Medicine in 2015.

Additionally, the FDA pointed out that under the Federal Food, Drug, and Cosmetic Act, drugs produced at facilities that require fees that have not been paid or self-identifying information has not been produced “are deemed to be misbranded and may be subject to refusal of admission to the U.S.”

The enforcement is part of the FDA’s crackdown in recent years on manufacturing facilities that consistently fail to meet the agency’s standards. Many of those facilities that have come under scrutiny in the past year are located across Asia, with the majority in China and India.

- here’s the RAPS article

Related Articles:
UPDATED: FDA castigates China's Zhejiang Hisun for 'systemic data manipulation'

Read more on

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.